Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
PharmacoFore, Inc. BIO Member Clinical Foci: CNS, Drug Discovery Wesley D. Sterman, MD Chief Executive Officer 75 Shoreway Road, Suite D San Carlos, CA 94070 USA www.pharmacofore.com Incorporated: 2004 Employees: 25 Ownership: Private 1-650-331-4010 HIGHLIGHTS Recent Upcoming PF329 ER HM Bio-MD system: Achieved human proof-of-concept demonstrating that our hydromorphone Bio-MD system is working as designed; Supports application of our technology to codones, other morphones, and amphetamines. Advance additional product candidates leveraging our BioMD and MPAR technologies into development. PF06 ER oxycodone Bio-MD and Bio-MD MPAR systems: Advanced our lead product candidates into development. Human proof-of-concept of the underlying Bio-MD technology demonstrated in PF329 clinical study. Raised USD $10 million from Founders Fund in initial closing of recent Series B round. Enter partnership with leading pharmaceutical companies to accelerate the development and commercialization of our 1) PF0713 IV sedative-hypnotic and antiemetic; and 2) our opioid Bio-MD and MPAR programs. Raise additional Series B equity capital in round led by Founders Fund. CORPORATE MISSION PharmacoFore (P4) is a privately-held biopharmaceutical company focused on creating novel medicines to improve upon the therapeutic utility of existing drugs, enhance patient care, and prevent the misuse, abuse, and overdose of prescription medications. We pursue carefully chosen programs in which: 1) the targets of our compounds have known mechanisms-of-action; and 2) human proofof-concept (hPOC) can be achieved early in the development process. Consequently, commercial launch can be achieved more rapidly. Our initial focus is on medicines that target the CNS and address unmet medical needs in areas such as sedation, pain management, and attention deficit hyperactivity disorder. As an innovator in the discovery of next-generation proprietary medicines, PharmacoFore applies insights and experience in medicinal chemistry, applied biology, clinical pharmacology, and early stage development to create and advance a pipeline of lower-risk development candidates. Our strategy is to leverage our expertise in these areas to generate data that demonstrate human clinical proofof-concept and support partnerships with leading pharmaceutical companies that have the capabilities to successfully develop and commercialize our products. We have achieved hPOC in our sedative-hypnotic program, demonstrating safety, efficacy and, importantly, competitive advantages which support our target product profile. The development and regulatory path for this program could lead to a commercial launch in the 201516 time-frame. This program has multiple product opportunities as an IV sedative-hypnotic and antiemetic, with a combined worldwide market of ~USD $3.6 billion. In addition, we have demonstrated hPOC of our molecular-level delivery technology. Our technology is broadly applicable to known drugs of abuse. Because our technology results in the release of known drugs systemically, the development risk and time to market are reduced, with multiple NCEs expected in 2016-18. PROPRIETARY TECHNOLOGY P4 has created a novel Bio-Activated Molecular Delivery technology designed to effectively deter prescription drug abuse at a molecular level. This technology does not a reformulation of existing opioids (1) in physical matrices that are easily circumvented by simple extraction methods; or (2) with aversive agents or antagonists that may expose patients to additional risks. P4’s opioid Bio-MD systems are designed to release clinically effective opioid drugs only when exposed to the correct physiologic conditions when orally ingested. P4's complementary technologies (i) MPAR provides multi-pill abuse resistance – removes incentive to misuse by self-escalating the dose, and protects from oral overdose; (ii) Polypharmacy protection against serious adverse events and deaths from polypharmacy. CORPORATE ALLIANCES To further develop our lead compounds, we aim to collaborate with global companies to accelerate the development and commercialization of our products. We are currently seeking partners for multiple programs. PF0713 Sedative-Hypnotic (human proof-of-concept – hPOC – achieved). Moderate-to-Severe Pain – Bio-Activated Molecular Delivery™ Systems and MPAR™ Technology for Abuse-Resistant Opioids: PF03 • Hydromorphone (hPOC achieved for hydromorphone Bio-MD™ system); • Oxymorphone; • Morphine • Oxycodone (advanced into development); • Hydrocodone. PF06 14th Annual BIO CEO & Investor Conference 158 Company Profiles PF16: Tapentadol. PF05 Reduced Opioid-Associated Side Effects (including OIC). PF0713 Antiemetic. PF08 Attention Deficit Hyperactivity Disorder (ADHD). Bio-MD Systems and MPAR Technology for Abuse-Resistant Amphetamine. PRODUCTS Name Indication Phase Milestone PF0713 IV sedative-hypnotic Phase II, IIa, IIb Human proof-of-concept - safety, efficacy, and competitive advantages - achieved. PF0713 Antiemetic Phase I Demonstrated highly potent antiemetic in animal studies. PF03 Tamper- and abuse-resistant hydromorphone Moderate-to-severe pain Phase I Human proof-of-concept of our prodrug's mechanismof-activation achieved. PF06 Tamper- and abuse-resistant oxycodone Moderate-to-severe pain Preclinical Product candidate advanced into development. PF06 Multi-pill abuse-resistant oxycodone Moderate-to-severe pain Preclinical Product candidate advanced into development. PF08 tamper- and abuse-resistant amphetamine ADHD Optimized Lead Expect to advance product candidate into development in 2H11. PF05 Opioid side effects Opioid-Induced Constipation Lead Series PF06 IR Hydrocodone Bio-MD MPAR Moderate-to-severe pain Optimized Lead PF06 IR Oxycodone Bio-MD MPAR Moderate-to-severe pain Lead Series PF03 ER Morphine (and OM) Bio-MD MPAR Moderate-to-severe pain Lead Series Expect to advance into development 1H12 SENIOR MANAGEMENT Wesley D. Sterman, MD, Chief Executive Officer • A. Gregory Sturmer, Chief Financial Officer • Thomas E. Jenkins, PhD, Chief Scientific Officer • Judy A. Magruder, Vice President • Narinder Banait, PhD, Vice President SCIENTIFIC ADVISORY BOARD David Alpers, MD, Washington School of Medicine • Douglas Gourlay, MD, Wasser Pain Management Centre, Mt. Sinai Hospital • Cynthia McCormick, MD, Former FDA Division of Anesthetic, Critical Care and Addiction Drug Products Director • Steven Passik, PhD, Memorial Sloan Kettering Cancer Center • Steven L. Shafer, MD, Columbia University and Editor-in-Chief, Anesthesia & Analgesia • Lynn Webster, MD, Lifetree Pain Clinic 14th Annual BIO CEO & Investor Conference 159 Company Profiles